CLINICAL TRIALS
Clinical Trials are necessary to evaluate the efficacy and safety of the new treatments in humans. To overcome the many challenges arising when conducting Clinical Trials, we strongly believe in the involvement of volunteers, patients and patient families.
CTH120 – FIRST IN HUMAN CLINICAL TRIAL
Safety and tolerability of CTH120, first-in-human phase I study encompassing three parts: Single and Multiple Ascending doses and potential Food Interaction
Status: Completed
CONNECTA’s first in class small molecule, CTH120, developed for the potential treatment of Fragile X Syndrome (FXS) and other neurodevelopmental disorders, is an Investigational Medicinal Product (IMP) that has completed its First in Human (FIH) clinical trial.
This clinical trial consisted of three parts: FIH-CTH120-SAD (Single Ascending Doses), FIH-CTH120-MAD (Multiple Ascending Doses) and FIH-CTH120-FI (Food Interaction) in healthy volunteers, and has been conducted at the Hospital del Mar Research Institute in Barcelona.
Learn more about this clinical trial at:
Clinicaltrials.gov (NCT06480968)
Registro Español de estudios clínicos (REec 2022-502209-13-01)
NEURAL BIOMARKERS IN FRAGILE X SYNDROME
Assessment of neural biomarkers in adult subjects with Fragile X syndrome and typically developing subjects
Status: Completed
The purpose of this non-interventional study was to assess neural biomarkers in adult subjects with Fragile X syndrome compared to those measured in a typically developing adults population.
This biomedical research project comprised a screening period and two cross sectional evaluations assessed during one month interval (test/re-test), starting on Visit 1 (Basal) and ending on Visit 2 (EOS). The study has been conducted at the Hospital del Mar Research Institute and Parc Taulí Research and Innovation Institute (Consorci Corporació Sanitaria Parc Taulí) in Barcelona.
Learn more about this biomedical research project at:
FXS-CTH120-01 – FIRST IN PATIENT CLINICAL TRIAL
Evaluation of the safety, tolerability, and effectiveness of CTH120 in adult males with Fragile X syndrome
Status: Recruiting
This Phase IIa randomized, double-blind, placebo-controlled, parallel groups, multicentre clinical trial, will assess safety, tolerability and efficacy of CTH120 75 mg twice daily in adult males with Fragile X syndrome (aged 18 to 45 years) at Hospital del Mar Research Institute (HMRI) and Parc Taulí Research and Innovation Institute (I3PT).
For more information contact with:
Hospital del Mar Research Institute (HMRI) – voluntarisassaig@researchmar.net or HMRI website
Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA) – neuroped@tauli.cat or I3PT website
Jornada Informativa – Informative Session – 24th October 2026
In Spanish (solamente en español)
Conoce los detalles de la próxima Jornada Informativa que tendrá un formato híbrido:
🗓️ 24 de Octubre de 2026
🕔 De 10:30h a 13:00 h
– Sesión presencial:
Hotel VP Sognio Metropolitano, Av. de la Reina Victoria, 12, Tetuán, 28003 Madrid.
El hotel dispone de aparcamiento de uso público con acceso directo al hotel (más información en la página web del hotel: https://lnkd.in/enXpd4d).
– Retransmisión online:
La sesión se retransmitirá en directo a través de la plataforma Microsoft Teams mediante el siguiente enlace: https://lnkd.in/e_M_5rQb
Informative Webinar – 27th May 2026
In Spanish (solamente en español)
Learn more about this clinical trial at:
Clinicaltrials.gov (NCT07654114)
Registro Español de estudios clínicos (REec 2025-522972-97-00)